

STRATEGY

The REX Peptide ETF seeks investment results that correspond generally to the price and yield, before fees and expenses, of the VettaFi Peptide IndexSM. This is the first pure play peptide ETF and the Index tracks companies positioned to advance the development, manufacturing and commercial adoption of peptide-based products, including therapeutics, supplements, cosmetics and medical devices. **Indices are unmanaged and are not available for direct investment.**

BENEFITS

WHOLE-CHAIN ACCESS

Drug developers, the contract manufacturers that build the molecules, the delivery and device companies, and consumer peptide products.

INDEXED EXPOSURE

Powered by VettaFi, an independent index provider, with a rules-based methodology: companies qualify on peptide revenue, pipeline or R&D spend.

DEMAND BEYOND OBESITY

Metabolic medicine is the largest piece of the market. In 2026 the FDA also approved peptide drugs for plaque psoriasis and for a rare blood cancer.

FUND INFORMATION

Fund Information

Fund Inception	10/14/2026
Primary Exchange	NASDAQ
CUSIP	761562792
Ticker	PEPT
Gross Expense Ratio	0.65%
Net Assets	\$500K

As of 10/14/2026

Performance

	1Mo	YTD	1Yr	3Yr	5Yr	Inception
Market Price	—	—	—	—	—	—
NAV	—	—	—	—	—	—

As of 9/30/2026

Top 10 Index Constituents

11.4%	Eli Lilly & Co.
9.6%	Ascendis Pharma A/S
9.5%	Novo Nordisk A/S
7.1%	Insulet Corporation
6.8%	Protagonist Therapeutics Inc
5.1%	Sanofi SA
5.0%	Rhythm Pharmaceuticals Inc
4.6%	Darling Ingredients Inc
4.5%	Viking Therapeutics Inc.
3.7%	Bachem Holding AG

Index constituents as of 9/30/2026

Index constituents are shown because the Fund had not commenced operations as of this document; they are not Fund holdings. Fund holdings are subject to change. The Fund tracks the VettaFi Peptide Index, rebalanced and reconstituted quarterly, and adjusts its portfolio shortly after Index changes are published. Source: VettaFi.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Performance current to the most recent month-end can be obtained by calling 1-844-802-4004. Short term performance, in particular, is not a good indication of the fund's future performance, and an investment should not be made based solely on returns.

Index: The VettaFi Peptide IndexSM is designed to track companies across four segments: therapeutics and medicine, manufacturing and medical devices, nutraceuticals and supplements, and cosmeceuticals and skincare, weighted 80% Core and 20% Diversified at each quarterly rebalance.

Market Price: The current price at which shares are bought and sold. Market returns are based upon the last trade price.

NAV: The dollar value of a single share, based on the value of the underlying assets of the fund minus its liabilities, divided by the number of shares outstanding. Calculated at the end of each business day.

ABOUT

The REX Peptides ETF is brought to you by REX Shares, an innovative ETP provider that specializes in alternative-strategy ETFs and ETNs. The firm created the MicroSectors[™] and co-created the T-REX product lines of leveraged and inverse tools for traders and recently launched a series of option-based income strategies. The firm is rooted in decades of experience building inventive solutions that solve for a range of specific challenges in investor and trader portfolios.



See back for Important
Performance Information

REXShares.com/PEPT | Info@REXfin.com | 1-844-802-4004

IMPORTANT INFORMATION

Investing in the Fund involves a high degree of risk. As with any investment, there is a risk that you could lose all or a portion of your investment in the Fund. Before investing you should carefully consider the Fund's investment objectives, risks, charges and expenses. This and other information is in the prospectus. Please read the prospectuses carefully before you invest. Investments involve risk. Principal loss is possible. For PEPT prospectuses, please visit rexshares.com/pept or call 1-844-802-4004.

THE FUND, TRUST, ADVISER, AND SUB-ADVISER ARE NOT AFFILIATED WITH THE FUND'S UNDERLYING SECURITIES.

The Fund will be concentrated (i.e., invests more than 25% of Fund assets) in an industry or a group of industries to the extent that the Index is so concentrated. Some or all of these risks may adversely affect the Fund's net asset value ("NAV") per share, trading price, yield, total return, and/or ability to meet its investment objective.

The value of the Fund, which focuses on underlying securities in the healthcare sector, may be more volatile than a more diversified pooled investment or the market as a whole and may perform differently from the value of a more diversified pooled investment or the market as a whole.

Peptide Companies Risk. Peptide Companies may be subject to substantial risks associated with the pharmaceuticals, biotechnology & life sciences industry, including extensive research and development costs, lengthy and uncertain regulatory approval processes, clinical trial failures, product safety concerns, intellectual property disputes, manufacturing complexities, supply chain disruptions, and rapid technological change.

Healthcare Sector Risk. The healthcare sector is subject to significant risks arising from, among other things, governmental regulation and participation in government healthcare programs, limits on governmental reimbursement for medical expenses, fluctuations in the cost of medical products and services, and product liability exposure.

Pharmaceuticals, Biotechnology & Life Sciences Industry Risk. Companies in the pharmaceuticals, biotechnology & life sciences industry may be adversely affected by extensive government regulation (including drug and device approval, manufacturing and marketing requirements, and reimbursement and pricing rules); the expiration or loss of, or challenges to, patent protection and other intellectual property rights; intense competition (including from generic drugs and biosimilar products); rapid product obsolescence and technological change; high research and development costs.

Concentration Risk. The Fund will be concentrated in an industry or a group of industries to the extent that the Index is so concentrated. To the extent the Fund has significant exposure in a single asset class or the securities of issuers within the same country, state, region, industry or sector, an adverse economic, business or political development may affect the value of the Fund's investments more than if the Fund were more broadly diversified.

Non-Diversification Risk. The Fund is classified as "non-diversified" under the 1940 Act. As a result, the Fund is only limited as to the percentage of its assets which may be invested in the securities of any one issuer by the diversification requirements imposed by the Internal Revenue Code of 1986, as amended (the "Code"). The Fund may invest a relatively high percentage of its assets in a limited number of issuers.

New Fund Risk. The Fund is a recently organized management investment company with limited operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

Index Provider Risk. Reliance on the Index Provider. There is no assurance that the Index Provider, or any of its agents, will compile the Index accurately, or that the Index will be constructed, maintained, compiled, reconstituted, rebalanced, composed, calculated or

disseminated accurately. The Index Provider and its agents do not provide any representation or warranty in relation to the quality, accuracy or completeness of data in the Index, and do not guarantee that the Index will be calculated in accordance with its stated.

Non-U.S. Securities Risk. Non-U.S. securities may be subject to higher volatility than securities of domestic issuers due to possible adverse political, social or economic developments, restrictions on foreign investment or exchange of securities, capital controls, lack of liquidity, currency exchange rates, excessive taxation, government seizure of assets, the imposition of sanctions by foreign governments, different legal or accounting standards, and less government supervision and regulation of securities exchanges in foreign countries.

Currency Risk. Changes in currency exchange rates affect the value of investments denominated in a foreign currency, and therefore the value of such investments in the Fund's portfolio. The Fund's net asset value could decline if a currency to which the Fund has exposure depreciates against the U.S. dollar or if there are delays or limits on repatriation of such currency. Currency exchange rates can be very volatile and can change quickly and unpredictably.

Equity Securities Risk. Equity securities are subject to changes in value, and their values may be more volatile than those of other asset classes. Equity securities prices fluctuate for several reasons, including changes in investors' perceptions of the financial condition of an issuer or the general condition of the relevant equity market, such as market volatility, or when political or economic events affecting an issuer occur.

Micro, Small and/or Mid Capitalization Companies Risk. Micro, small and/or mid capitalization companies may be more vulnerable to adverse general market or economic developments, and their securities may be less liquid and may experience greater price volatility than large capitalization companies as a result of several factors, including limited trading volumes, fewer products or financial resources, management inexperience and less publicly available information.

Volatility Risk. Volatility is the characteristic of a security, an index or a market to fluctuate significantly in price within a short time period. The Fund may invest in securities or financial instruments that exhibit more volatility than the market as a whole. Such exposures could cause the Fund's net asset value to experience significant increases or declines in value over short periods of time.

Passive Investment Risk. The Fund is not actively managed. The Fund invests in securities included in or representative of the Index regardless of investment merit. The Fund generally will not attempt to take defensive positions in declining markets.

Premium/Discount Risk. As with all ETFs, Fund Shares may be bought and sold in the secondary market at market prices. Although it is expected that the market price of Fund Shares will approximate the Fund's NAV, there may be times when the market price of Fund Shares is more than the NAV intraday (premium) or less than the NAV intraday (discount) due to supply and demand of Fund Shares or during periods of market.

Funds distributed by: Foreside Fund Services, LLC, not affiliated with Rex Shares, LLC.